trial

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

NCTId NCT00570063
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 35 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2008-02-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
35 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-11
Primary completion
2008-02-18
Eligibility
ALL · 18 Years · 99 Years

Interventions & indications

Drugs
PF-02545920

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

10 total
Glendale, United StatesGlendale, United StatesLemon Grove, United StatesParamount, United StatesParamount, United StatesSan Diego, United StatesNew Haven, United StatesWillingboro, United StatesOklahoma City, United StatesOklahoma City, United States

Linked catalysts

1
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Effica — primary completion2008-02-18

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE2
Primary Completion Date
2008-02-18
Status
TERMINATED
relationships
The graph out of here
drug
PF-02545920
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication